Guggenheim Capital
IDXG

Guggenheim Capital’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Guggenheim Capital’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-314
Closed -$5K – 3021
2016
Q3 		$5K Buy
+314
New +$8.68K ﹤0.01% 2878

Other funds holding IDXG

BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Virtu KCG Holdings
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Ancora Advisors
Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Glenmede Trust
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Guggenheim Capital's IDXG Position: Q4 2016 in Review

Guggenheim Capital sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q4 2016, closing a stake of 314 shares — an estimated $5K sold.

Guggenheim Capital first reported a position in IDXG in Q3 2016 and held it in 1 quarter. The position peaked at $5K in Q3 2016. 14 funds tracked by Wall St. Rank hold IDXG as of Q4 2016.

  • Guggenheim Capital reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Guggenheim Capital sold 314 Interpace Biosciences, Inc. Common Stock shares in Q4 2016, an estimated $5K.
  • Guggenheim Capital first reported a position in Interpace Biosciences, Inc. Common Stock in Q3 2016 and held it in 1 quarter.
  • Guggenheim Capital's Interpace Biosciences, Inc. Common Stock position peaked at $5K in Q3 2016.
  • 14 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q4 2016.

Based on Guggenheim Capital's 13F filing for Q4 2016, filed 14 Feb 2017.